Harvoni Boasts Near-Perfect Hep C Cure Rates in Cirrhotics

May 20, 2015

Gilead Sciences' Harvoni (ledipasvir/sofosbuvir), with or without ribavirin, cures 92 to 100 percent of people with genotype 1 of hepatitis C virus (HCV) and cirrhosis, MedPage Today reports. Researchers conducted a pooled analysis of data from Phase II and III trials LONESTAR, ELECTRON, ELECTRON-2, 337-0113, ION-1, ION-2 and SIRIUS. They presented their findings at the Digestive Disease Week annual meeting in Washington, DC.

Ninety-one percent of the participants had cirrhosis. About two-thirds had failed a previous treatment attempt, and of that group two-thirds had taken a protease inhibitor-inclusive regimen.

Ninety-two percent of those who took Harvoni for 12 weeks achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure), while those who took the tablet for 24 weeks had a 98 percent cure rate. Those who took Harvoni and ribavirin for a respective 12 weeks and 24 weeks had a 96 percent and 100 percent cure rate.

Among the treatment-experienced participants who took 12 weeks of just Harvoni, 90 percent were cured. If they took ribavirin and doubled the treatment time, this cure rate increased to 96 percent.

To read the MedPage Today story, click here.

To read the study abstract, click here.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.hepmag.com/article/Harvoni-cirrhosis-27265-2037919846